Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

NCT03741127 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Rimiducid may be administered as indicated

Sponsor

Poseida Therapeutics, Inc.

Collaborators

[object Object]